A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates whether it is safe to administer a helper peptide vaccine with
dabrafenib and trametinib. This study will also evaluate the effects of the combination of
the peptide vaccine and dabrafenib and trametinib on the immune system. We will monitor these
effects by performing tests in the laboratory on participants' blood and tumor samples.